JAC Advance Access originally published online on December 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 186-188
© 2003 The British Society for Antimicrobial Chemotherapy
Correspondence |
Linezolid resistance in clinical isolates of Staphylococcus aureus
1 University College London Hospital, Department of Clinical Microbiology, London; 2 University College London Hospital, Cardiothoracic Surgery, London; 3 Royal Free and University College London Medical School, Bloomsbury Institute of Intensive Care, London; 4 GR Micro Ltd, London, UK
Keywords: oxazolidinone, resistance, Staphylococcus aureus, linezolid
| The first 10% of the full text of this article appears below. |
Sir,
Linezolid is the first oxazolidinone antibiotic to be licensed for treatment of Gram-positive infections. It is active against methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate S. aureus (GISA) and vancomycin-resistant enterococci (VRE).1 It inhibits the formation of the initiation complex formed with mRNA, fMet-tRNA and the 30S ribosomal subunit. Mutations to the central loop of domain V of 23S rRNA have been associated with resistance to linezolid in several species in vitro.2 There has been one report of resistance of MRSA in a clinical infection, a patient with dialysis-related peritonitis.3
Acknowledgements
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Locke, M. Hilgers, and K. J. Shaw Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700) Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5265 - 5274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vidaillac, S. N. Leonard, and M. J. Rybak In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4712 - 4717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Feng, A. Lupien, H. Gingras, J. Wasserscheid, K. Dewar, D. Legare, and M. Ouellette Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance Genome Res., July 1, 2009; 19(7): 1214 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Shaw, S. Poppe, R. Schaadt, V. Brown-Driver, J. Finn, C. M. Pillar, D. Shinabarger, and G. Zurenko In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4442 - 4447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Skripkin, T. S. McConnell, J. DeVito, L. Lawrence, J. A. Ippolito, E. M. Duffy, J. Sutcliffe, and F. Franceschi R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3550 - 3557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miller, C. J. Dunsmore, C. W. G. Fishwick, and I. Chopra Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1737 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Besier, A. Ludwig, J. Zander, V. Brade, and T. A. Wichelhaus Linezolid Resistance in Staphylococcus aureus: Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1570 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hong, X. Li, J. Wang, C. Sloan, and C. Cicogna Sequential Linezolid-Resistant Staphylococcus epidermidis Isolates with G2576T Mutation J. Clin. Microbiol., October 1, 2007; 45(10): 3277 - 3280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Gill, G. K. Abruzzo, A. M. Flattery, A. S. Misura, K. Bartizal, and E. J. Hickey In Vivo Efficacy of a Novel Oxazolidinone Compound in Two Mouse Models of Infection Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3434 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Goff and M. J. Dowzicky Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial J. Med. Microbiol., September 1, 2007; 56(9): 1189 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hayman, A. P. R. Wilson, M. Singer, and G. Bellingan Effect of linezolid and teicoplanin on skin staphylococci J. Antimicrob. Chemother., June 1, 2007; 59(6): 1281 - 1282. [Full Text] [PDF]
|
|
|
|
|
|
F. Goldstein The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus J. Antimicrob. Chemother., January 1, 2007; 59(1): 1 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. R. Wilson, J. A. Cepeda, S. Hayman, T. Whitehouse, M. Singer, and G. Bellingan In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients J. Antimicrob. Chemother., August 1, 2006; 58(2): 470 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5024 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Swoboda, S. Fritz, M. E. Martignoni, R. A. Feldhues, T. Hoppe-Tichy, M. W. Buchler, and H. K. Geiss Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report J. Antimicrob. Chemother., October 1, 2005; 56(4): 787 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. E. Drummond and D. S. Reeves Reduced time to publication and increased rejection rate J. Antimicrob. Chemother., June 1, 2005; 55(6): 815 - 816. [Full Text] [PDF]
|
|
|
|
|
|
S. Reilley, E. Wenzel, L. Reynolds, B. Bennett, J. M. Patti, and S. Hetherington Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy Volunteers Antimicrob. Agents Chemother., March 1, 2005; 49(3): 959 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shibata, K. Kondo, R. Katsuyama, K. Kawazoe, Y. Sato, K. Murakami, Y. Takaishi, N. Arakaki, and T. Higuti Alkyl Gallates, Intensifiers of {beta}-Lactam Susceptibility in Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., February 1, 2005; 49(2): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jacqueline, D. Navas, E. Batard, A.-F. Miegeville, V. Le Mabecque, M.-F. Kergueris, D. Bugnon, G. Potel, and J. Caillon In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., January 1, 2005; 49(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Meka, H. S. Gold, A. Cooke, L. Venkataraman, G. M. Eliopoulos, R. C. Moellering Jr, and S. G. Jenkins Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus J. Antimicrob. Chemother., October 1, 2004; 54(4): 818 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Cooper, G. F. Medley, S. P. Stone, C. C. Kibbler, B. D. Cookson, J. A. Roberts, G. Duckworth, R. Lai, and S. Ebrahim Methicillin-resistant Staphylococcus aureus in hospitals and the community: Stealth dynamics and control catastrophes PNAS, July 6, 2004; 101(27): 10223 - 10228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Kim, H.-C. Jang, H. J. Nam, Y. S. Lee, B. S. Kim, W. B. Park, K. D. Lee, Y. J. Choi, S. W. Park, M.-d. Oh, et al. In Vitro Activities of 28 Antimicrobial Agents against Staphylococcus aureus Isolates from Tertiary-Care Hospitals in Korea: a Nationwide Survey Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1124 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Hardy, P. M. Hawkey, F. Gao, and B. A. Oppenheim Methicillin resistant Staphylococcus aureus in the critically ill Br. J. Anaesth., January 1, 2004; 92(1): 121 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Paterson, A. W. Pasculle, and K. McCurry Linezolid: The First Oxazolidinone Antimicrobial Ann Intern Med, November 18, 2003; 139(10): 863 - 864. [Full Text] [PDF]
|
|
|
|
|
|
A. Sinclair, C. Arnold, and N. Woodford Rapid Detection and Estimation by Pyrosequencing of 23S rRNA Genes with a Single Nucleotide Polymorphism Conferring Linezolid Resistance in Enterococci Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3620 - 3622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Howe, M. Wootton, A. R. Noel, K. E. Bowker, T. R. Walsh, and A. P. MacGowan Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3651 - 3652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Strommenger, C. Kettlitz, G. Werner, and W. Witte Multiplex PCR Assay for Simultaneous Detection of Nine Clinically Relevant Antibiotic Resistance Genes in Staphylococcus aureus J. Clin. Microbiol., September 1, 2003; 41(9): 4089 - 4094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M Lomaestro Resistance to Linezolid. Are We Surprised? How Hard Should We Look? Ann. Pharmacother., June 1, 2003; 37(6): 909 - 911. [Full Text] [PDF]
|
|
|
|
|
|
G. Sakoulas, H. S. Gold, L. Venkataraman, R. C. Moellering Jr, M. J. Ferraro, and G. M. Eliopoulos Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility J. Antimicrob. Chemother., April 1, 2003; 51(4): 1039 - 1041. [Full Text] [PDF]
|
|
|
|
|
|
I. A. Critchley, D. C. Draghi, D. F. Sahm, C. Thornsberry, M. E. Jones, and J. A. Karlowsky Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001 J. Antimicrob. Chemother., March 1, 2003; 51(3): 639 - 649. [Abstract] [Full Text] [PDF]
|
|